Off-label and unlicensed medicine use — branching viva

Opening (warm-up)

Examiner: "You are the general paediatric registrar. I am handing you two scenarios. In the first, a 3-month-old is being started on propranolol oral for an infantile haemangioma; the propranolol is licensed for adult hypertension. In the second, our neonatal pharmacy has made up a caffeine citrate solution because no licensed preparation exists at the strength we need for a preterm infant. Classify each prescription for me." [1]

Model answer: The propranolol is off-label — a licensed product (it carries a marketing authorisation, for adult hypertension) used outside one or more of its licensed terms (here the age, indication and dose for the infant). The caffeine solution is unlicensed — there is no valid marketing authorisation for that product or formulation in the jurisdiction; it is compounded because no licensed paediatric preparation exists at the required strength. Both are legal, common and often evidence-based; neither is an error. [1] [6]

Branch 1 — probe the definition boundary

Examiner: "So what exactly separates off-label from unlicensed? Could the propranolol ever be unlicensed?" [6]

Model answer: The pivot is whether a marketing authorisation exists for the product at all. Off-label always starts from a product that is licensed somewhere; one or more terms (age, indication, route, dose, formulation) are exceeded. Unlicensed means no licence exists for the product or formulation. The propranolol would become unlicensed only if the pharmacy compounded a formulation that has no licence — for example, if no licensed propranolol liquid existed and the pharmacy made one from raw material. As long as a licensed propranolol product is being used outside its terms, it remains off-label. [5] [6]

Examiner (corner): "And how is that different from an investigational product in a clinical trial?" [7]

Model answer: An investigational medicinal product is also unlicensed, but it is governed by a trial protocol, ethics approval and the research pharmacy, not by my bedside safe-use pathway. Routine off-label or unlicensed care is my governance responsibility; trial use is the protocol's. [7]

Branch 2 — why is this so common in children?

Examiner: "Why is so much of what we prescribe to children outside the licence?" [6]

Model answer: Five drivers converge on a paediatric evidence gap. First, the market — children are a small, fragmented market, so the commercial return on paediatric programmes is low. Second, trial logistics — paediatric trials need consent, assent, age-stratified cohorts and relatively larger blood volumes per sample. Third, developmental pharmacokinetics — absorption, distribution, metabolism and excretion change with age, so adult data cannot be scaled. Fourth, the formulation gap — many drugs have no age-appropriate liquid or palatable form. Fifth, regulatory lag — medicines are licensed for adults first and the paediatric licence follows years later, if at all. [6]

Examiner: "Give me the prevalence headline." [1]

Model answer: Conroy's 2000 BMJ European survey was the landmark — a substantial proportion of ward prescriptions were unlicensed or off-label. The peak prevalence is in neonates and intensive care, and Nir-Neuman's 2018 study found it had not fallen over a decade in NICU and PICU. [1] [9]

Branch 3 — the governance pathway (the core)

Examiner: "Walk me through what you actually do when a child needs a medicine outside its licence." [7]

Model answer — six steps, in order: [7]

1. Is there a licensed alternative that meets the need and is locally available? If yes, use it. [7]
2. Is there high-quality evidence (guideline, systematic review, formulary monograph)? If not, seek alternatives or Medicines Committee advice. [6]
3. Choose the safest formulation — prefer a licensed product used off-label over an unlicensed compounded or imported product; confirm stability and strength with pharmacy. [5]
4. Document the indication, the evidence base, the weight-based dose (child weighed in kilograms), the family discussion and the local approval status. [7]
5. Counsel and obtain consent (and assent where competent); explain the medicine is off-label and why it is the best choice. [7]
6. Monitor and report — watch efficacy and adverse drug reactions, and report every suspected reaction to the national pharmacovigilance scheme. [8]

Examiner (corner): "What makes a use high-risk, and what changes then?" [7]

Model answer: High-risk features are a narrow therapeutic index, a neonate or infant, an IV inotrope or sedative, or a compounded or imported formulation. For high-risk use I obtain senior sign-off and notify the local Medicines Committee before the first dose, confirm stability and supply with pharmacy, and intensify monitoring. [7]

Branch 4 — adverse drug reactions and pharmacovigilance

Examiner: "The infant on the off-label propranolol becomes bradycardic and hypotensive after a dose increase. Talk me through it." [8]

Model answer: Treat the child first; govern the prescribing afterwards. I would assess ABCs, stop or hold the suspect medicine, escalate to the consultant and pharmacist, and give supportive care (propranolol toxicity is managed supportively; severe cases may need glucagon). Once the child is stable, I would document the event, review the dose against a paediatric reference, and report the suspected adverse drug reaction through the national scheme — for off-label and unlicensed medicines the post-marketing database is thin, so reporting on suspicion is exactly how the evidence gap closes. Bellis's 2013 study linked off-label and unlicensed medicines to a higher ADR rate, which is why monitoring and reporting matter more, not less, here. [8]

Branch 5 — the regional regulatory picture

Examiner: "Has regulation fixed this?" [10]

Model answer: Partially. The EU Paediatric Regulation (2007) requires a Paediatric Investigation Plan and rewards paediatric data. In the US, BPCA (paediatric exclusivity) and PREA (mandatory paediatric assessment), made permanent under FDASIA, have driven many paediatric label changes. But Lindell-Osuagwu's 2014 before-and-after study found the EU Regulation increased the data without yet translating into a clear fall in off-label prescribing at the ward level. The honest answer is that the frameworks are necessary but not sufficient — bedside governance and reporting still do the heavy lifting. [10]

Closing probe

Examiner: "Give me one sentence a parent would understand." [7]

Model answer: "This medicine works well for children with your child's condition, but it was first studied and licensed for adults — so I am using my best evidence to choose the dose, I will watch your child closely, and I will record and report anything that happens, so that other children benefit too." [7]